For research purposes only — not for human consumption — 18+ only
Weight Loss
Retatrutide 10mg
$100.00
GLP-1/GIP/glucagon triple agonist. Research applications in metabolic syndrome and obesity.
Retatrutide (LY3437943), developed by Eli Lilly, is a next-generation triple receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. Unlike semaglutide (GLP-1 only) or tirzepatide (dual GLP-1/GIP), retatrutide's glucagon receptor activity significantly increases energy expenditure, making it one of the most potent metabolic research compounds available. Phase II clinical trials demonstrated average weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks in the 12mg cohort — results that significantly exceed previously available compounds. Retatrutide represents a major advancement in the pharmacology of metabolic disease.
Molecular Data
Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3
Triple Receptor Mechanism
Retatrutide acts on three receptor pathways simultaneously: GLP-1 receptors stimulate insulin secretion and suppress appetite; GIP receptors (at 8.9× the potency of endogenous GIP) enhance insulin response and energy storage regulation; and glucagon receptors increase hepatic glucose output and energy expenditure. This triple mechanism produces effects on appetite, insulin sensitivity, and metabolic rate that are synergistically greater than any single or dual pathway approach.
Clinical Trial Data
In the pivotal Phase II obesity trial, participants receiving 12mg weekly retatrutide achieved mean weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks. Secondary outcomes included significant improvements in triglycerides, HDL cholesterol, blood pressure, and fasting glucose. The compound is currently in Phase III TRIUMPH trials evaluating long-term safety and efficacy. Improvements in liver steatosis (MASLD) have also been documented in a sub-study of the Phase II trial.
Comparison to Other GLP-1 Compounds
Retatrutide's triple agonism provides meaningfully superior weight reduction compared to semaglutide (GLP-1 mono-agonist, ~15% weight loss at 68 weeks) and tirzepatide (GLP-1/GIP dual agonist, ~21% at 72 weeks in SURMOUNT-1). The addition of glucagon receptor activity drives increased energy expenditure through thermogenesis — a mechanism absent in the other compounds — accounting for much of the additional efficacy observed.
Metabolic and Hepatic Effects
Beyond weight reduction, retatrutide demonstrates significant hepatic benefits. Research in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) shows meaningful reductions in liver fat content, hepatic inflammation markers (ALT, AST), and fibrosis biomarkers. These effects are attributed to the combined action of GLP-1 mediated insulin sensitisation and glucagon receptor activation improving hepatic lipid metabolism.
Future Research
Retatrutide is currently progressing through Phase III TRIUMPH clinical trials. Research interest extends beyond obesity to type 2 diabetes, MASLD, cardiovascular risk reduction, and potentially kidney disease. The triple agonist approach has established a new paradigm in metabolic peptide pharmacology.
Product Usage
This product is intended as a research chemical only. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only.
Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.
This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabelled as a drug, food or cosmetic.
Reviews
There are no reviews yet.